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INTRODUCTION
Hypertension provides both despair and hope. Despair because it is quantitatively 
the largest risk factor for cardiovascular diseases, is growing in prevalence, and is poorly 
controlled  virtually  everywhere.  Hope  because  prevention  is  possible  and  because 
treatment  can  control  hypertension  in  all  most  all  patients  with  consequent  marked 
reduction in stroke and heart attack.
It  should  be  noted  that  cardiovascular  diseases  are  the  leading  cause  of  death 
worldwide,  not  only in economically  developed countries but  also in the developing 
world.  In  turn,  hypertension  is  overall  the  major  contributor  to  the  risks  for 
cardiovascular  diseases.  The  over  all  world  wide  prevalence  of  hypertension  is 
approximately 26% of the adult populationi, with marked differences between countries. 
The increasing prevalence of hypertension is primarily a consequence of the population 
becoming older and obese. Despite overwhelming evidence that effective treatment of 
hypertension  is  associated  with  a  significant  reduction  of cardiovascular  events,  the 
number  of  patients  who are  aware of  their  condition and who achieve  adequate  BP 
control remains unacceptably low.
Albumin  excretion  and  microalbuminuria  are  currently  drawing a  great  deal  of 
attention  in  the  medical  literature.  Much of this  attention derives  from the  fact  that 
albumin excretion is a risk factor for kidney failure, stroke, and cardiovascular and all-
cause mortality, particularly for persons with diabetes and/or hypertensionii.
Based  on  the  data  from the  Heart  Outcomes  Prevention  and  Evaluation  Study 
(HOPE STUDY)iii, it is clear that the presence of microalbuminuria is an signal from 
kidney  that  cardiovascular  risk  is  increased  and  that  vascular  responses  are  altered. 
Microalbuminuria is a highly specific predictor of the simultaneous occurrence of both 
cardiac and vascular abnormalities.
Data  from  the  LIFEiv study  show  that  the  ECG  strain  pattern  of  ST-segment 
depression and T-wave inversion in the lateral precordial leads is a predictor of heart 
failure. This strain pattern has been associated with increased left ventricular mass and 
depressed left ventricular function.
This  study  focuses  on  the  incidence  of  microalbuminuria  and  left  ventricular 
hypertrophy among hypertensive patients along with demographic analysis.
AIMS AND OBJECTIVES
TO FIND OUT THE INCIDENCE OF MICRO-ALBUMINURIA AND LEFT 
VENTRICULAR  HYPERTROPHY   AMONG   HYPERTENSIVE  PATIENTS 
WITHOUT ASSOCIATED CONDITIONS  LIKE DIABETES MELLITUS, STROKE, 
ISCHAEMIC HEART DISEASE AND  RENAL DISEASES. 
STUDY POPULATION
A  hospital  based  cross-sectional  study  was  conducted  among  hypertensive 
patients who attend the out-patient department of cardiology in Chengalpattu medical 
college  hospital,  Chengalpattu  from march  2009  to  December  2009  to  find  out  the 
incidence  of  microalbuminuria  and left  ventricular  hypertrophy Among hypertensive 
patients. All patients between the age of 35 and 65 who attend the hypertensive clinic 
were screened for the following diseases and excluded from the study.
1. Diabetes mellitus.
2. Cerebro-vascular accident.
3. Coronary artery disease.
4. Kidney diseases (creatinine above 2 mg/dl).
5. Urinary tract infection. 
Diabetes  mellitus  was  ruled  out  by  fasting  and  post  prandial  blood  sugar. 
Coronary artery disease and stroke was ruled out by history, physical examination and 
appropriate  investigation.  Urinary  tract  infection was  ruled  out  by  urine culture  and 
kidney diseases by blood urea and serum creatinine. Patients who were on ACE/ARB 
drugs were excluded from the study. Study subjects who were anemic and who had 
fever were excluded from the study.  Only patients with raised blood pressure without  
the above conditions were the study subjects.
BLOOD PRESSURE MEASUREMENTv
Once the patient was selected by the above criteria  the BP has been recorded in 
the following manner. Several steps have been taken to minimize the variability.
1. Having the subjects rest silently and comfortably (with back and arm support if 
seated) for about 5min before measurement.
2. Abstaining from drinking caffeine or alcohol containing beverages or tobacco 
use within 30 min before a BP measurement.
3. Questioning the subject regarding the most recent meal or evacuation of bowl or 
bladder.
4. Centering the bladder of cuff over the brachial artery with its lower edge within 
2.5 cm of the antecubital fossa.
5. Assuring that the arm was supported at the level of the heart.
6. Listening over the brachial artery by using the bell of stethoscope with minimal 
pressure exerted over the skin.
7. BP measurements, the cuff typically should be inflated 20mm hg higher than the 
pressure at which the palpable pulse at the radial artery disappears.
8. Attempting  to  avoid  “terminal  digit  preference,”  there  should  be  an  equal 
number of readings ending in 0,2,4,6, or 8 mmhg.
9. Measurement of BP in both arm typically are obtained at the initial visit, and the 
arm with higher BP was used thereafter if the difference was greater than 10/5 
mmhg.
10.On each occasion at least two readings were  taken with as much as time as it 
was practicable separateable. If reading more than 5mmhg additional readings 
were taken until they where close.
11.For diagnosis at least three sets of readings at one week apart.   
CLASSCIFICATION:
Hypertension was defined based on seventh joint national committee criteriavi
JNC 7 SBP/DBP
NORMAL <120/<80
PRE HYPERTENSION 120-139/80-89
STAGE 1 HYPERTENSION 140-159/90-99
STAGE 2 HYPERTENSION >160/>100
ANTHROPOMETRIC METHODOLOGY
Patients  nutritional  status  was  quantified  by  comparing  weight  and  height-the 
Quetelet index.
Body mass index=weight in Kg/(height in meters)2
WHO classification of obesityvii.
CATEGOR
Y
BMI
UNDER WEIGHT <18.5
HEALTHY WEIGHT 18.5-24.9
OVERWEIGHT 25-29.9
MODERATE OBESE 30-34.9
SEVERE OBESE 35-39.9
MORBID OBESE >40
ELECTROCARDIOGRAPHY METHODOLOGY
Left ventricular hypertrophy was diagnosed by ecg-romhilt and estes point score 
system.
ROMHILT AND ESTES POINT SCORE SYSTEMviii.
1. INCREASED QRS MAGNITUDE=3 POINTS.
2. ST-T ABNORMALITY=3 POINTS.
3. LEFT ATRIAL ENLARGEMENT=3 POINTS.
4. LEFT AXIS DEVIATION=2 POINTS.
5. INCREASED VENTRICULAR ACTIVATION TIME=1 POINT.
A SCORE OF 5 POINTS OR MORE INDICATES LVH.
MICROALBUMINUREA MEYHODOLOGY METHODix
This test was based on antigen antibody reaction. The polyclonal goat anti-human 
albumin  present  in  the  reagent  reacts  with  albumin  present  in  the  urine  and  forms 
precipitate which can be measured by immunoturbidity method. The precipitate formed 
is proportional to the amount of albumin present in urine.
REAGENTS
Antiserum consist of polyclonal goat anti human albumin,phosphate buffer saline 
and sodium azide. Buffer consist of saline,accelerator and sodium azide.
Calibrator contains defibrinated human plasma diluted with phosphate buffered 
saline.
SAMPLE
Spot midstream urine sample was collected. Study subjects were advised not to 
smoke and exercise before sample collection. 
PROCEDURE
50 micro liter of urine sample was taken in a test tube to this 900 micro liter of 
buffer and 100 micro liter of antiserum was added. The mixture was incubated at 37 
degree  centigrade  for  5  min.  the  precipitate  obtained  was  read  immune 
turbidometrically at 340 nanometer.   
ESTIMATION OF URINARY CREATININE
PRINCIPLE
Creatinine present in the urine reacts with alkaline picrate in the reagent to form 
reddish orange colored complex known as creatinine picrate whish can be measured 
calorimetrically. This method was known as Jaffes reaction.
REAGENTS
0.75 N sodium hydroxide
0.04 M picric acid
Creatinine standard of various concentrations.
SAMPLE
The urine sample was diluted with distilled water in 1:20 dilution.
PROCEDURE
250 micro liter of piric acid and 250 micro liter of sodium hydroxide was taken in 
a test tube to this 50 micro liter of urine was added. This mixture was kept at room 
temperature. Then the reading was taken at 515 nanometer calorimetrically.
ESTIMATION OF ALBUMIN CREATININE RATIOx
Albumin creatinine ratio =   micro albumin in mg/L  x 1000.
                                               Urine creatinine in mg/L
The ratio  gives  the  value  of  micro  albumin in  milligram per  gram of  urinary 
creatinine.
 ACR IN Mg PER Gm OF 
CREATININE
REFERENCE RANGE
<30 NORMAL
30-300 MICROALBUMIN UREA
>300 MACROALBUMIN UREA
The chi-square test was used in the statistical analysis. Informed consent from the 
study subjects and ethical clearance from the institute was obtained for this project.
REVIEW OF LITERATURE
Affecting 1 billion people worldwide,  systemic hypertension remains the most 
common, readily identifiable, and reversible risk factor for myocardial infarction, stroke, 
heart failure, atrial fibrillation, aortic dissection, and peripheral arterial disease. Because 
of escalating obesity and population aging in developed and developing countries, the 
global burden of hypertension is rising and projected to affect 1.5 billion persons, one 
third  of  the  world's  population,  by  the  year  2025xi.  Thus,  hypertension  remains  the 
leading cause of death worldwide and one of the world's great public health problems.
The  asymptomatic  nature  of  the  condition  delays  diagnosis.  Hypertension 
currently is defined as a usual BP of 140/90 mmxii Hg or higher, BP levels for which the 
benefits of pharmacological treatment have been definitively established in randomized 
placebo-controlled trials.
LIFETIME RISK OF HYPERTENSION
Hypertension is an increasingly important medical and public health issue. The 
prevalence of hypertension increases with advancing age to the point where more than 
half of people aged 60 to 69 years old and approximately three-fourths of those aged 70 
years and older are affectedxiii. The age-related rise in SBP is primarily responsible for an 
increase in both incidence and prevalence of hypertension with increasing agexiv. 
Framingham Heart Study investigators recently reported the lifetime risk of hypertension to be 
approximately 90% for men and women who were nonhypertensive at 55 or 65 years old and survived 
to age 80 to 85xv.
BLOOD PRESSURE AND CARDIOVASCULAR RISK
Data from observational studies involving more than 1 million individuals have 
indicated that death from both ischemic heart disease and stroke increases progressively 
and linearly from BP levels as low as 115 mm Hg systolic and 75 mm Hg diastolic 
upwardxvi. For every 20 mm Hg systolic or 10 mm Hg diastolic increase in BP, there is a 
doubling of mortality from both ischemic heart disease and stroke.
Basis for Reclassification of Blood Pressure
Because  of  the  new data  on  lifetime  risk  of  hypertension  and the  impressive 
increase  in  the  risk  of  cardiovascular  complications associated  with  levels  of  BP 
previously considered to be normal, the JNC 7 report has introduced a new classification 
that includes the term "prehypertension" for those with BPs ranging from 120 to 139 mm 
Hg  systolic  and/or  80  to  89  mm  Hg  diastolic  blood pressure  (DBP).  This  new 
designation  is  intended  to  identify those  individuals  in  whom early  intervention  by 
adoption of healthy lifestyles could reduce BP, decrease the rate of progression of BP to 
hypertensive levels with age, or prevent hypertension entirely.
CARDIOVASCULAR DISEASE RISK
The relationship between BP and risk of CVD events is continuous, consistent, 
and independent of other risk factors. The higher the BP, the greater is the chance of 
heart attack, HF, stroke, and kidney diseases. The presence of each additional risk factor 
compounds  the  risk  from hypertensionxvii. Management of  these  other  risk  factors  is 
essential and should follow the established guidelines for controlling these coexisting 
problems that contribute to overall cardiovascular risk.
IMPORTANCE OF SYSTOLIC BLOOD PRESSURE
Impressive  evidence  has  accumulated  to  warrant  greater  attention to  the 
importance of SBP as a major risk factor for CVDs. Changing patterns of BP occur with 
increasing age. The rise in SBP continues throughout life, in contrast to DBP, which 
rises until approximately 50 years old, tends to level off over the next decade, and may 
remain the same or fall later in life. Diastolic hypertension predominates before 50 years 
of age, either alone or in combination with SBP elevation. The prevalence of systolic 
hypertension increases with age, and above the age of 50 years, systolic hypertension 
represents the most common form of hypertension. DBP is a more potent cardiovascular 
risk factor than SBP until age 50; thereafter, SBP is more importantxviii.
Clinical  trials  have  demonstrated  that  control  of  isolated  systolic hypertension 
reduces  total  mortality,  cardiovascular  mortality, stroke,  and  HF  eventsxix.  Both 
observational  studies and clinical  trial  data  suggest  that  poor  SBP control  is  largely 
responsible for the unacceptably low rates of overall BP controlxx.
In the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack 
Trial (ALLHAT) and Controlled Onset Verapamil Investigation of Cardiovascular End 
Points (CONVINCE) trial, DBP control rates exceeded 90%, but SBP control rates were 
considerably less (60 to 70%)xxi. Poor SBP control is at least in part related to physician 
attitudes.  Most physicians have been taught that the diastolic pressure is more important 
than  SBP  and  thus  treat accordingly.  Greater  emphasis  must  clearly  be  placed  on 
managing systolic hypertension.
PREVENTION OF HYPERTENSION: PUBLIC HEALTH CHALLENGES
The  prevention  and  management  of  hypertension  are  major  public health 
challenges.  If  the  rise  in  BP  with age  could  be  prevented  or  diminished,  much  of 
hypertension, cardiovascular and renal disease, and stroke might be prevented. A number 
of important causal factors for hypertension have been identified, including excess body 
weight;  excess dietary sodium intake; reduced physical activity; inadequate intake of 
fruits, vegetables, and potassium; and excess alcohol intakexxii. The prevalence of these 
characteristics is high.
Because the lifetime risk of developing hypertension is very high, a public health 
strategy that complements the hypertension treatment strategy is warranted. In order to 
prevent BP levels  from rising,  primary  prevention  measures  should be introduced to 
reduce or minimize these causal factors in the population, particularly in individuals with 
prehypertension. A  population  approach  that  decreases  the  BP  level  in  the  general 
population by even modest amounts has the potential to substantially reduce morbidity 
and  mortality  or  at  least  delay  the  onset  of hypertension.  For  example,  it  has  been 
estimated that a 5 mm Hg reduction of SBP in the population would result in a 14% 
overall reduction in mortality due to stroke, a 9% reduction in mortality due to CHD, and 
a 7% decrease in all-cause mortality xxiii.
PREVALENCE OF MICROALBUMINUREA
In  1974,  Parving  et  al.xxiv  demonstrated  the presence  of  microalbuminuria  in 
patients with untreated essential hypertension. The Losartan Intervention for Endpoint 
Reduction (LIFE) trial in hypertensive patients with electrocardiographic signs of left 
ventricular hypertrophy (LVH)  the mean age of the 8029 patients was 66 years, 54% 
were women.  Microalbuminuria  was  found in  23% and macroalbuminuria  in  4% of 
patients.
General population study such as   Prevention of Renal and Vascular End Stage 
Disease (PREVEND) show an 8 to 11.5% prevalence of microalbuminuria in individuals 
with hypertension xxv. 
Microalbuminuria: A Genoa Investigation on Complications [MAGIC] xxvi  Study From 
the  Department  of  Internal  Medicine  and  the  Institute  of  General  Pathology  (G.S.), 
University  of  Genoa;  and the  Division  of  Medicine,  Galliera  (C.C.)  and S.  Martino 
(G.G.) Hospitals, Genoa, Italy.
The  prevalence  of  microalbuminuria  and  its  relationship with  several 
cardiovascular risk factors and target organ damage were evaluated in a cohort of 787 
untreated  patients  with  essential hypertension.  Albuminuria  was  measured  as  the 
albumin-to-creatinine ratio  in  three nonconsecutive,  first  morning urine samples. The 
was 6.7%. Albuminuric patients were more likely to be men and to be characterized by 
higher blood pressure, body mass index, and uric acid levels and lower HDL cholesterol 
and  HDL  cholesterol-to-LDL  cholesterol  ratio.  The  log  of  ACR  showed  a  positive 
although weak correlation with age and a stronger correlation with BP (DBP and mean 
BP), but it was unrelated to BMI and the duration of hypertension. Patients with major 
ECG changes were more likely to have microalbuminuria (OR, 1.76; 95% CI, 1.06 to 
2.95;  P<.04) and showed higher levels of albuminuria and BP, older age, and a longer 
duration of hypertension compared with patients with normal ECGs.
The prevalence of microalbuminuria in the general population is in the range of 5 
to 7% according to several  large cohort studies:  PREVEND, Nord-Trøndelag Health 
Study (HUNT), AusDiabxxvii .
The  prevalence  of  microalbuminuria  in  patients  with  hypertension is  less 
consistent in large population or cohort studies, varying from 8 to 23%. 
Microalbuminuria can be detected in up to 40% of the population with established 
hypertension,  particularly  in  those  patients not  controlled  satisfactorily  by  anti-
hypertensive therapyxxviii. Even blood pressure levels between 130 and 139/80 and 89 
mmhg are significantly associated with microalbuminuriaxxix .
ASSOCIATION OF MICROALBUMINUREA WITH AGE AND SEX
The Nord-Trøndelag Health Study (HUNT)xxx, Norway, 1995 to  997 (n=65 258) 
conducted a 4.3-year follow-up of 2307 men  and  3062 women (20 years old) with self-
reported treated hypertension. The main outcome measures were relative risk (RR) of 
all-cause mortality according to increasing albuminuria,  defined at  different  levels of 
albumin-to-creatinine ratio (ACR). There was a consistent positive association between 
increasing ACR and all-cause mortality in men. The adjusted RR for ACR in the fourth 
quartile (1.70 mg/mmol) was 1.6 (95% CI, 1.0 to 2.6), compared with ACR in the first 
quartile (<0.55 mg/mmol). The corresponding RR in women was 1.5 (95% CI, 0.8 to 
3.1).  They found a  positive  association between mortality  and increasing number  of 
urine samples with ACR above different  cutoff levels,  especially  in men.  In 3 urine 
samples, the lowest ACR level associated with mortality in men was 0.86 mg/mmol, RR 
1.6 (95% CI, 1.1 to 2.4). The sex differences persisted after exclusion of those who died 
during the first year of follow-up, those with hypertension not treated optimally, and 
those with known cardiovascular disease. 
The  association  between  ACR and all-cause mortality  was  stronger  in  treated 
hypertensive  men  than  in  women. The  persistent  sex  differences  indicate  that 
hypertensive women tolerate MA better than men and that MA in women should be 
interpreted differently than in men.
The American Diabetes Association defines microalbuminuria as excretion of 30–
299 mg of albumin in a 24-hour collection, with values above 300 being defined as 
macroalbuminuriaxxxi .
The gender-specific ACR cutoffs of 17–249 mg/g for men and 25–354 mg/g for 
women that have been proposed by Warram et alxxxii . B Hitha, JM Pappachan et al from 
Kottayam Medical College, Kottayam, Kerala, India conducted an cross-sectional cohort 
study in patients with essential hypertension attending the medical outpatient clinic and 
those admitted to the medical wards at the Kottayam Medical College, between May 
2005 and October 2006.the sample size  was 150.It  was found that  the patients with 
longer duration of hypertension, older age and adverse lipid profile are more prone to 
develop MA.
EVALUATION OF MEASURES OF URINARY ALBUMIN EXCRETION IN 
EPIDEMIOLOGIC STUDIES
INTERMAP,( International Study of Macronutrients and Blood Pressure)xxxiii
Department of Preventive Medicine, Feinberg School of Medicine, Northwestern 
University,  Chicago,  IL.  June 22,  2004 evaluated the Measures of  Urinary Albumin 
Excretion.
. Twenty-four-hour  urinary  albumin  excretion  (UAE)  is  considered the  gold 
standard for  determining albumin level  in epidemiologic studies,  but  this  measure is 
inconvenient and often unavailable. Simpler alternatives include the albumin: creatinine 
ratio (ACR) and urinary albumin concentration (UAC) obtained from a single sample. 
The authors assessed the strengths and weaknesses of ACR and UAC as alternatives to 
UAE using albumin measurements from two 24-hour urine samples collected in 1996–
1999 from  4,678  participants  aged  40–59  years  in  the  International Study  of 
Macronutrients and Blood Pressure (17 population samples from four countries). The 
authors compared ACR and UAC with regard to correlations with UAE, daily within-
person  variability, and  associations  with  known  predictors  of  UAE.  Rank-order 
correlations of ACR with UAE were 0.949 and 0.942 for men and women, respectively, 
versus 0.881 and 0.816 for  UAC. Mean within-person coefficients of variation were 
34.0–40.0% for the three measures, with the smallest values being observed for UAC. 
Average correlations with blood pressure were similar for UAE, ACR, and UAC, but the 
correlation with body mass index was lower for ACR (0.118 for ACR and 0.188 for 
UAC vs.  0.211 for UAE) because of high correlation between body mass index and 
creatinine level. Thus, UAC and ACR are acceptable alternatives to the more complex 
UAE, and the simpler UAC may be preferable to ACR in some respects.
ECG AND LEFT VENTRICULAR HYPERTROPHY
Ary L Goldberger, MD et al  xxxiv found the sensitivity of the various criteria for 
moderate to severe LVH was in the 30 to 60 percent range, with specificities in the 80 to 
90 percent range. Although it is relatively insensitive, the ECG does have prognostic 
significance. Hypertensive patients with echocardiographically proven LVH who also 
meet ECG criteria have a greater left ventricular mass than those without the expected 
ECG changesxxxv .
Echocardiography is  the procedure of  choice for  diagnosing LVH. It  can also 
permit quantitation of LV mass and give important information about the etiology of 
LVH (such as aortic or mitral valve disease, or hypertrophic cardiomyopathy). However, 
the ECG may be used when echocardiography is unavailable or too expensivexxxvi .
The electrocardiographic diagnosis of LVH is quite reliable when very prominent 
voltage is seen in conjunction with left atrial and ST-T abnormalities, leftward axis, or 
widening  of  the  QRS.  As  noted  above,  however,  false  negative  and  false  positive 
diagnoses  are  not  uncommon.  Patients  with LVH may fail  to  show voltage criteria, 
especially if they have only mild hypertrophy or underlying obstructive lung disease. 
The sensitivity is also reduced in women and in subjects with obesityxxxvii . On the other 
hand,  increased  voltage  is  a  common  normal  variant,  particularly  in  young  adult 
malesxxxviii.
The  electrocardiogram is  a  useful  but  imperfect  tool  for  detecting  LVH.  The 
utility of the ECG relates to its being relatively inexpensive and widely available. The 
limitations of the ECG relate to its moderate sensitivity or specificity depending upon 
which of the many proposed sets of criteria are appliedxxxix .
MICROALBUMINURIA AS AN EARLY MARKER FOR CARDIOVASCULAR 
DISEASE
Excretion of albumin in the urine is highly variable, ranging from nondeductible 
quantities to milligrams of albumin and even grams of albumin. Microalbuminuria is 
defined as low levels of urinary albumin excretion of 30 to 300 mg/xl . It is interesting 
that microalbuminuria also is found frequently in seemingly healthy individuals (5 to 
7%)xli .  The variable  excretion of  albumin in the  urine  is  related to  the risk for  the 
individual  to  develop cardiovascular  (CV)  disease:  Absence  or  very  low  levels  of 
albuminuria is associated with low CV risk, whereas the CV risk increases markedly 
with increasing amount of albumin in the urine (even within the now considered normal 
range). The predictive power of urinary albumin levels for CV risk is independent of 
other CV  risk  factors  and  not  only  is  present  in  individual  with  diabetes and/or 
hypertension  but  also  in  healthy  individuals.  Treatments that  lower  albuminuria  are 
associated  with  CV  protection,  as demonstrated  in  randomized,  controlled  trials  of 
patients  with diabetes  as  well  as  in  patients  with hypertension.  There  is preliminary 
evidence  that  albuminuria  lowering  is  CV protective in  healthy  individuals  with  an 
elevated albumin excretion rate. Higher levels of urinary albumin seem to reflect the 
ordinary inter  individual  variability  in  (renal  and  systemic)  endothelial function.  In 
conclusion, albuminuria  seems  to  be  a  sensitive  marker  very  early  in  life for  the 
susceptibility of an individual to CV disease. It therefore may be an ideal target for early 
primary prevention using CV-protective therapy regimens.
Microalbuminuria is defined as small quantities of albumin in the urine, ranging 
from 30 to 300 mg/d. Below 30 mg/d (or 20 mg/L) is considered normal, and above 300 
mg/d (or 200 g/L) is considered to be macroalbuminuria (also called overt albuminuria).
MICROALBUMINUREA AND CARDIOVASCULAR RISK
Framingham Offspring Studyxlii  the association of urinary albumin excretion (spot 
urine albumin indexed to creatinine [UACR] and the incidence of CVD events and all-
cause  mortality in  1568  non-hypertensive,  non-diabetic   participants  (mean  age,  55 
years; 58% women) free of CVD was examined .On follow-up (median, 6 years), 54 
participants (20 women) developed a first CVD event, and 49 (19 women) died. After 
adjustment for established risk factors,  increasing UACR was associated with greater 
risk of CVD (hazards ratio [HR] per SD increment in log UACR, 1.36; 95% CI, 1.00 to 
1.87) and death (HR per  SD increment  in  log UACR, 1.55;  95% CI,  1.10 to 2.20). 
Participants with UACR greater than or equal to the sex-specific median (3.9 µg/mg for 
men, 7.5 µg/mg for women) experienced a nearly 3-fold risk of CVD (adjusted HR, 
2.92; 95% CI, 1.57 to 5.44;  P<0.001) and a borderline significantly increased risk of 
death (adjusted HR, 1.75;  95% CI,  0.95 to 3.22;  P=0.08) compared with those with 
UACR below the median. The increased CVD risk associated with UACR at or above 
the  median  remained robust  in  analyses  restricted  to  individuals  without 
microalbuminuria (n=1470)  and  in  subgroups  with  intermediate  (n=1469)  and  low 
(n=1186) pretest probabilities of CVD.
Brantsma et  al.xliii  showed  that  individuals  with  microalbuminuria  had an 
approximately  four-fold  increase  in  the  risk  for  developing subsequent  new-onset 
diabetes than those with low normal urinary albumin levels, even after correcting for 
baseline glucose and insulin levels or after excluding those with impaired fasting glucose 
or metabolic syndrome. Brantsma et al.  similarly found that microalbuminuria increased 
the risk for  de novo hypertension by two-fold as compared with normal albuminuria 
levels.
In  the  patient  with  hypertension,  microalbuminuria  has  been discovered  as  an 
important factor, although it has not penetrated all guidelines. The groups of Bigazzi and 
Campese  et alxliv reviewed the importance of microalbuminuria as a CV risk predictor. 
Larger cohort studies confirmed this to be independent from other risk markers in the 
general  hypertensive  population  (MONICA)xlv ,  a  hypertensive  cohort  with  LVH 
(LIFE)xlvi ,  and  in  individuals with  already  increased  CV  risk  (Heart  Outcomes 
Prevention Evaluation [HOPE])xlvii . 
In the above studies, microalbuminuria was associated and clustered with other 
widely known CV risk factors (age, diabetes, hypertension, LVH, overweight, metabolic 
syndrome, etc.) that could explain the increased CV risk. Careful correction for such 
factors and post hoc selection of "healthy" individuals in the large general population 
cohorts did still reveal the marked and overwhelming independent predictive power of 
microalbuminuria. This was confirmed by the recent Framingham publication of Arnlov 
et al.xlviii  that showed elegantly that in normotensive individuals without diabetes and 
with  normal  renal  function,  microalbuminuria  remains  a  strong predictor  for  CV 
outcome.
LOWERING MICROALBUMINURIA AND CV PROTECTION
Albuminuria seems to be an independent  and strong predictor for  CV disease. 
Several  strategies  are  available  to lower  urinary  albumin  excretion  in  the 
microalbuminuric  range. Widely  known  is  the  albuminuria-lowering  effect  of 
antihypertensive agents,  in  particular  those  that  intervene  in  the  renin-angiotensin-
aldosterone system. However, statins and glucose-aminoglycans also have been proved 
to  lower  albuminuria  xlix.  Asselbergs  et  al.l indeed  showed that  the  lowering  of 
albuminuria with the angiotensin-converting enzyme inhibitor fosinopril  tended to be 
cardio protective. A recent  post hoc analysis of the LIFE trial found similar results in 
hypertensive  patients:  The  more  the  angiotensin  II  antagonist losartan  lowered 
albuminuria, the more the patient was cardio protected, irrespective of the effect on other 
CV risk factors li .
Future CV trials  involving drugs  that  target  albuminuria  more  specifically are 
needed to resolve the issue of whether specific lowering of albuminuria results in CV 
protection  and  whether  this  is a  cost-effective  health  care  approach.  In  this  issue’s 
Frontiers in Nephrology, De Jong and Curhanlii  review the public health perspectives of 
screening  and  monitoring  of  urine albumin  excretion  in  relation  to  CV  disease 
prevention.
LEFT VENTRICULAR HYPERTROPHY AND HEART FAILURE IN 
HYPERTENSIVE PATIENTS
One well-known risk factor for heart failure is hypertension, with 39% of new 
cases in men and 59% in women ascribed to hypertensionliii .
Independent  of  blood  pressure,  electrocardiographic  (ECG)  left  ventricular 
hypertrophy (LVH) is also associated with an increased risk of new heart failureliv . This 
risk is decreased by the prevention of ECG LVH. Antihypertensive therapy that reduced 
blood pressure has been shown to decrease ECG LVH, and regression of ECG LVH has 
been  correlated  with  a  significant  reduction  in  cardiovascular  death,  myocardial 
infarction  (MI),  and  stroke,  regardless  of  antihypertensive  treatment  or  degree  of 
decrease in blood pressurelv .
A very recent  publication from Leoncini  et  allvi examined the presence of sub 
clinical  CV damage,  localized in the heart and in the carotid artery,  in hypertensive 
patients with either microalbuminuria and a creatinine clearance <60 ml/min/m. After 
adjusting for duration of hypertension, mean blood pressure, smoking habits and age, the 
risk of left ventricular hypertrophy and/or carotid atherosclerosis was increased by 43% 
with each SD reduction in creatinine clearance and by 89% with each SD increase in 
microalbuminuria. Mildly increased serum creatinine has been shown to be associated 
with angiographic  coronary  artery disease in  womenlvii.  An increased left  ventricular 
mass has been amply demonstrated in patients  with microalbuminurialviii . These and 
other recently reviewedlix data indicate that microalbuminuria can be considered as an 
integrated marker of sub clinical organ damage starting with the early stages of arterial 
hypertension. Microalbuminuria is then a useful tool for risk profiling.
RESULTS AND DISCUSSION
AGE WISE DISTRIBUTION
Age No. Of Persons %
35-45 14 14.4
46-55 36 37.1
56-65 47 48.5
TOTAL 97 100
Table No: 1
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After applying the exclusion criteria the majority (48.5 %) of the study subjects 
were in the age group between 56 and 65 yrs. 37 % of study subjects were between 46 
and 55 yrs. Only 14% were younger than   46 yrs.
SEX WISE DISTRIBUTION
Sex No Of Male/Female %
Male 21 21.6
Female 76 78.4
TOTAL 97 100
Table No: 2
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78 % of the study subjects were female and remaining were males.
BMI WISE DISTRIBUTION
BMI
NO. Of 
Persons %
UNDER WEIGHT 7 7.2
HEALTHY WEIGHT 56 57.8
OVERWEIGHT 24 24.8
MODERATE OBESE 9 9.2
SEVERE OBESE 1 1
MORBID OBESE 0 0
TOTAL 97 100
Table No: 3
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As  per  the  WHO  classification  of  obesity  the  majority  (57.8%)  of  the  study 
subjects  were  in  the  BMI  (Body  Mass  Index)between  18.5  and  24.9(healthy 
weight).34.8% were over weight by BMI. Only minimal study subjects were moderate 
and severe obese.
RESIDENCE WISE DISTRIBUTION
RESIDENCE No. Of Persons %
RURAL 78 80.4
URBAN 19 19.6
TOTAL 97 100
Table No: 4
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Majority (80.4 % ) of selected subjects were from rural area.
DURATION OF HYPERTENSION AND ITS 
DISTRIBUTION
Duration of SHT No. Of Persons %
< 1 year 22 22.7
1 year - 2 year 36 37.1
2 year - 3 year 12 12.4
3 year - 5 year 19 19.6
> 5 8 8.2
Total 97 100
Table No: 5
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DURATION OF HYPERTENSION AND ITS DISTRIBUTION
From the history obtained from the study subjects majority (37.1 % ) admitted 
that they were taking treatment for hypertension between one to two yrs.19 % of the 
study subjects were taking treatment for 3 to 5 yrs as per the history. Only meager were 
in the category of more than 5 yrs duration.
SYSTOLIC BLOOD PRESSURE AND ITS DISTRIBUTION
SBP Total No Of Persons %
< 120 20 20.6
121- 140 44 45.4
141 - 160 27 27.8
> 160 6 6.2
TOTAL 97 100
Table No: 6
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SYSTOLIC BLOOD PRESSURE AND ITS DISTRIBUTION
45.4 % of the study subjects had systolic blood pressure (SBP) reading between 
121 to 140at the time of examination after following the necessary procedure.27.8 % of 
study subjects had SBP between 141 and 160. Negligible number of study subjects had 
SBP of more than 160 and less than 120.
DIASTOLIC BLOOD PRESSURE AND ITS DISTRIBUTION
DBP Total No Of 
Persons
%
< 80 3 3.1
81 - 90 73 75.3
91 - 100 21 21.6
> 100 0 0
TOTAL 97 100
Table No: 7
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75.3 % of study subjects had diastolic blood pressure between 81 and 90.
INCIDENCE OF MICROALBUMINUREA
MICROALBUMINUREA 
(MAU) OUTCOME %
MAU + 22 22.7
MAU - 75 77.3
TOTAL 97 100
Table No: 8
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INCIDENCE OF MICROALBUMINUREA
Out of 97 study subjects who were selected for the study between  march 2009 to 
December  2009  ,  22.7  %  of  the  study  subjects  had  microalbuminuria  by 
immunoturbidity method. 
In the Losartan Intervention for Endpoint Reduction (LIFE)lx trial in hypertensive 
patients with electrocardiographic signs of left ventricular hypertrophy (LVH)  the mean 
age of the 8029 patients was 66 years, 54% were women. Microalbuminuria was found 
in 23% and macroalbuminuria in 4% of patients. 
Agewall et allxi  reported an 23% prevalence of microalbuminuria in a population 
of hypertensive patients who were selected as at high risk for cardiovascular disease.
In our study as mentioned above, 22.7 % had microalbuminurea.
INCIDENCE OF LEFT VENTRICULAR HYPERTROPHY
LVH OUTCOME %
LVH + 20 20.6
LVH - 77 79.4
TOTAL 97 100
Table No: 9
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INCIDENCE OF LEFT VENTRICULAR HYPERTROPHY
ECG was taken in all  study subjects and it was found that 21 % of the study 
subjects had left ventricular hypertrophy. 
B  Hitha,  JM Pappachan  et  al  lxii  conducted  a  cross-sectional  cohort  study  in 
patients with essential  hypertension attending the medical outpatient clinic and those 
admitted to the medical wards at the Kottayam Medical College, between May 2005 and 
October 2006. It was found that 26.67 % had microalbuminuria and 10.67 % had ECG 
evidence of left ventricular hypertrophy. 
The  difference  in  incidence  of  left  ventricular  hypertrophy  was  due  to  the 
difference in ECG methodology and sample size.
RELATION BETWEEN MICROALBUMINUREA AND AGE
Age
Total No Of 
Persons MAU + MAU - % Of Positivity
35-45 14 2 12 14.3
46-55 36 8 29 22.2
56-65 47 12 34 25.5
Table No: 10
Chi-square value = 6.3  ,  P value = < 0.05 
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RELATION BETWEEN MICROALBUMINUREA AND AGE
Majority (25.5 %) of study subjects belong to the age group between 56 to 65 yrs. 
Only 14 % of the study subjects belong to the age group between 35 to 45 yrs. As the 
age increases the occurrence of microalbuminuria also increases.
Ricardo  Pereira  Silva  et  al  lxiii conducted  a  study  in  a  group  of  hypertensive 
patients (73 individuals) and in a group of patients with coronary artery disease (39 
individuals) was determined and compared with a control group (43 individuals).There 
was  a  statistically  significant  correlation  between  age  and  the  occurrence  of 
microalbuminuria. 
Our study also showed a statistical significant difference (p <0.05) between the 
age group and the onset of microalbuminuria.
RELATION BETWEEN AGE AND LEFT VENTRICULAR HYPERTROPHY
Age
NO. Of 
Persons LVH + LVH - % Of Positivity
35-45 14 0 14 0
46-55 37 10 27 27
56-65 46 10 36 21.7
Table No: 11
Chi-square value = 3.6, P value = > 0.05                     
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RELATION BETWEEN AGE AND LEFT VENTRICULAR HYPERTROPHY
27 % of the study subjects who had levt ventricular hypertrophy belong to the age 
group between 46 to 55 and 21.7 % belong to age group between 56 and 65. There is no 
consistent increase in the incidence of leftventricular hypertrophy with age. 
Sybolt  O.de  vireo,  Wilfred  F.  Heesen  et  al  lxiv from  Department  of  health 
sciences,University  hospital  Groninger:  The  Netherlands  conducted  an  community 
based survey program  in 1996 in the general population with 277 subjects. It was found 
that the correlation between age and LV mass in the study was very week (p >0.001).
In our study also the correlation between age and LV mass was very week.
RELATION BETWEEN SEX AND MICROALBUMINUREA
Sex
No Of 
Male/Female MAU+ MAU-
%  Of 
Positivity
Male 21 5 16 23.8
Female 76 17 59 22.4
Table No: 12
Chi-square value = 9.3, P value = < 0.01                            
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RELATION BETWEEN SEX AND MICROALBUMINUREA
The  above  table  (No.12)  shows  a  strong  correlation  between  sex  and 
microalbuminuria. The p value was less than 0.01 which signifies a statistical difference 
between male and female with regard to microalbuminuria.
The Nord-Trøndelag Health Study (HUNT)lxv, Norway, 1995 to 1997 (n=65 258) 
conducted a 4.3-year follow-up of 2307 men and 3062 women (20 years old) with self-
reported treated hypertension. The main outcome measures were relative risk (RR) of 
all-cause mortality according to increasing albuminuria,  defined at different levels of 
albumin-to-creatinine ratio (ACR). There was a consistent positive association between 
increasing  ACR  and  all-cause  mortality  in  men.  They  found  a  positive  association 
between mortality and increasing number of urine samples with ACR above different 
cutoff levels, especially in men.
Our study also showed a strong association between sex and the incidence of 
microalbuminuria.
RELATION BETWEEN SEX AND LEFT VENTRICULAR HYPERTROPHY
Sex No Of Male/Female ECG LVH + ECG LVH- %
Male 21 6 15 28.6
Female 76 14 62 18.4
Table No: 13
Chi-square value = 6.9, P value = < 0.01 
RELATION BETWEEN SEX AND LEFT VENTRICULAR HYPERTROPHY
As per the table (no. 13), out of 21 males 6 had left ventricular hypertrophy (28.6 
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%) where as it was only 18.4 5 out of 76 females. Regarding the relationship between 
sex and left ventricular hypertrophy our study showed a very strong statistical difference 
between sex and left ventricular hypertrophy.
ANTIKAINEN R.  et  al  lxvi studied  2994  hypertensive  patients  in  whom  an 
electrocardiogram was recorded while not on treatment. It was found that patients with 
the presence of ECG LVH were more often men.
RELATION BETWEEN BODY MASS INDEX AND MICROALBUMINUREA
BMI
NO. Of 
Persons MAU + MAU -
% Of 
Positivity
UNDER WEIGHT 7 3 4 42.9
HEALTHY WEIGHT 56 14 42 25
OVERWEIGHT 24 5 19 20.8
MODERATE OBESE 9 0 9 0
SEVERE OBESE 1 0 1 0
MORBID OBESE 0 0 0 0
Table No: 14
Chi-square value = 6.2, P value = > 0.05 
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RELATION BETWEEN BODY MASS INDEX AND MICROALBUMINUREA
From the table no. 14 it was evident that body mass index has not showed any 
correlation with microalbuminuria since majority (57.8 %) of the study subjects were 
with  body  mass  index  in  healthy  weight.  Hence  there  was  no  statistical  significant 
difference  between  body  mass  index  and  microalbuminuria.  Though  in  general  the 
probability  of  occurrence  of  microalbuminuria  increases  as  the  body  mass  index 
increases.
Ricardo  Pereira  Silva  et  al  lxvii conducted  a  study  in  a  group  of  hypertensive 
patients (73 individuals) and in a group of patients with coronary artery disease (39 
individuals) was determined and compared with a control group (43 individuals). The 
prevalence of microalbuminuria among obese or overweight patients(13%) was lower 
than that of the patients with normal weight (17.9%)
RELATION BETWEEN BODY MASS INDEX AND LEFT VENTRICULAR 
HYPERTROPHY
BMI
NO. Of 
Persons LVH + LVH -
% Of 
Positivity
UNDER WEIGHT 7 0 7 0
HEALTHY WEIGHT 56 15 41 26.8
OVERWEIGHT 24 5 19 20.8
MODERATE OBESE 9 0 9 0
SEVERE OBESE 1 0 1 0
MORBID OBESE 0 0 0 0
Table No: 15
Chi-square value = 7.1, P value = > 0.05 
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RELATION BETWEEN BODY MASS INDEX AND LEFT VENTRICULAR 
HYPERTROPHY
The above table no.15 shows that left ventricular hypertrophy was present only in 
the subjects who were in healthy weight and over weight. Left ventricular hypertrophy 
was absent  in rest  of the subjects.  Since majority (57.8 %) of the study subjects as 
mentioned  early  were  in  the  healthy  weight,  the  percentage  of  Positivity  for  left 
ventricular hypertrophy was also observed more among them. 
ANTIKAINEN R. et al  lxviii studied 2994 hypertensive patients in 2003 in whom 
an electrocardiogram was recorded while not on treatment. It was found that systolic 
(SBP) and diastolic (DBP) blood pressure and pulse pressure were positively related to 
the increasing ECG voltage, while body mass index (BMI) was inversely related.
RELATION  BETWEEN  DURATION  OF  HYPERTENSION  AND 
MICROALBUMINUREA
Duration of 
SHT 
No. Of 
Persons MAU + MAU -
% 
Positivity
< 1 year 22 7 15 31.8
1 year - 2 year 27 6 21 22.2
2 year - 3 year 9 2 7 22.2
3-4 years 12 5 7 41.6
4-5 years 11 1 10 9.1
> 5 years 16 1 15 6.25
Table No: 16
Chi-square value = 1.3, P value = > 0.05 
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RELATION BETWEEN DURATION OF HYPERTENSION AND 
MICROALBUMINUREA
From  the  above  table  no.  16  it  was  evident  that  there  was  no  statistical 
significance  between  the  duration  of  hypertension  and  the  occurrence  of 
microalbuminuria. Only a prospective cohort study can prove the strength of association 
between  the  duration  of  hypertension  and  the  occurrence  of  microalbuminuria  by 
calculating the relative risk.
Roberto Pontremoli et al  lxix in the Microalbuminuria: A Genoa Investigation on 
Complications  [MAGIC])  Study,   the  prevalence  of  microalbuminuria  and  its 
relationship  with  several  cardiovascular  risk  factors  and  target  organ  damage  were 
evaluated in a cohort of 787 untreated patients with essential hypertension. Albuminuric 
patients were more likely to be men and to be characterized by higher blood pressure, 
body mass index, and uric acid levels and lower HDL cholesterol and HDL cholesterol-
to-LDL cholesterol ratio. The log of ACR showed a positive although weak correlation 
with age and a stronger correlation with BP (DBP and mean BP), but it was unrelated to 
BMI and the duration of hypertension. 
RELATION  BETWEEN  SYSTOLIC  BLOOD  PRESSURE  AND 
MICROALBUMINUREA 
SBP
NO. Of 
Persons MAU + MAU - % Of Positivity
< 120 20 1 19 5
121- 140 43 11 32 25.6
141 - 160 28 8 20 28.6
> 160 6 2 4 33.3
Table No: 17
Chi-square value = 1.7, P value = > 0.05 
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RELATION BETWEEN SYSTOLIC BLOOD PRESSURE AND 
MICROALBUMINUREA 
From the table no.  17 it  was evident  that  there was no statistical  significance 
between systolic blood pressure and the occurance of microalbuminuria.
Massimo Cirillo et al  lxx in an Cross-sectional analysis of data in 1998 for 1567 
participants in The Gubbio Population Study (677 men and 890 women), found that 
diastolic blood pressure related directly to microalbuminuria (P<.001) when compared 
to systolic blood pressure.
RELATION  BETWEEN  DIASTOLIC  BLOOD  PRESSURE  AND 
MICROALBUMINUREA 
DBP
NO. Of 
Persons MAU + MAU -
% Of 
Positivity
< 80 3 0 3 0
81 - 90 73 16 57 21.9
91 - 100 21 6 15 28.6
> 100 0 0 0 0
Table No: 18
Chi-square value = 5.9, P value = < 0.05 
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RELATION BETWEEN DIASTOLIC BLOOD PRESSURE AND 
MICROALBUMINUREA 
Our study showed a  statistically  significant  difference between diastolic  blood 
pressure  and  the  occurrence  of  microalbuminuria.  As  the  diastolic  blood  pressure 
increases,  the  number  of  percentage  of  study  subjects  who  were  positive  for 
microalbuminuria was also increased.
Roberto Pontremoli  et  al  lxxi conducted  a  large clinical  trial  in  1997 with 787 
patients  (438 men,  349 women) with hypertension found a stronger correlation with 
diastolic blood pressure and microalbuminuria.
RELATION  BETWEEN  SYSTOLIC  BLOOD  PRESSURE  AND  LEFT 
VENTRICULAR HYPERTROPHY
SBP Total No Of Persons LVH + LVH -
% Of 
Positivity
< 120 20 0 20 0
121- 140 43 12 31 27.9
141 - 160 28 7 21 25
> 160 6 1 5 16.6
Table No: 19
Chi-square value = 1.4, P value = > 0.05 
SBP vs LVH
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RELATION  BETWEEN  SYSTOLIC  BLOOD  PRESSURE  AND  LEFT 
VENTRICULAR HYPERTROPHY
Out of 20 subjects who had left ventricular hypertrophy, 12 had systolic blood 
pressure between 121 to 140 and 7 had systolic blood pressure between 140 to 160. By 
applying chi square test it was not statistically significant.
J.C.N. Mbanya et al  lxxii conducted a cross sectional study in 2001 at a referral 
hospital in the city of Yaoundé (Cameroon) over a six-month period. It was found that 
diastolic  blood  pressure  was  significantly  higher  in  the  patients  with  ventricular 
hypertrophy,  and  shortening  fraction  was  negatively  correlated  with  diastolic  blood 
pressure (r = -0.40; p = 0.01) but not with systolic blood pressure.
RELATION  BETWEEN  DIASTOLIC  BLOOD  PRESSURE  AND  LEFT 
VENTRICULAR HYPERTROPHY
DBP
Total No Of 
Persons LVH + LVH -
% Of 
Positivity
< 80 3 0 3 0
81 - 90 73 15 58 20.5
91 - 100 21 5 16 23.8
> 100 0 0 0 0
Table No: 21
Chi-square value = 6.1, P value = < 0.05 
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RELATION BETWEEN DIASTOLIC BLOOD PRESSURE AND LEFT 
VENTRICULAR HYPERTROPHY
Out of 21 study subjects of diastolic blood pressure between 91 to100, 23.8 % had 
left ventricular hypertrophy were as it was only 20.5 5 among the study subjects who 
had diastolic blood pressure between 81 to 90. There was a constant increase in the left 
ventricular hypertrophy Positivity with the increase in diastolic blood pressure and it 
was statistically significant.
J.C.N. Mbanya et al  lxxiii conducted a cross sectional study in 2001 at a referral 
hospital in the city of Yaoundé (Cameroon) over a six-month period. It was found that 
diastolic  blood  pressure  was  significantly  higher  in  the  patients  with  ventricular 
hypertrophy,  and  shortening  fraction  was  negatively  correlated  with  diastolic  blood 
pressure (r = -0.40; p = 0.01) but not with systolic blood pressure.
CONCLUSION
In our study 22.7 % of the study subjects had microalbuminuria and 20.6 % had 
left  ventricular  hypertrophy.  There  was  a  strong  statistical  association  between 
microalbuminuria  and age,  sex  and diastolic  blood pressure.  Similarly  the  statistical 
association between left ventricular hypertrophy and diastolic blood pressure was strong. 
Both microalbuminuria and left ventricular hypertrophy were not statistically associated 
with body mass index and systolic blood pressure.
PROFORMA
Name :
Age :
Sex :
Address :
Duration Of Hypertension :
History of CAD,CKD,DM :
Treatment :
Blood Pressure :
Height :
Weight :
INVESTIGATIONS
Haemoglobin :
Total & Differential count :
Urine Sugar,Albumin&Deposits.
Blood Sugar(Fasting&Postprandial).
Blood Sugar:
Serum Creatinine:
Microalbuminuria and urine creatinine:
Left ventricular hypertrophy by ECG:
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